within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR26_DarunavirAndRitonavir;

model DarunavirAndRitonavir
  extends Pharmacolibrary.Drugs.ATC.J.J05AR26;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AR26</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Darunavir is a protease inhibitor used in combination with ritonavir, a pharmacokinetic enhancer, for the treatment of Human Immunodeficiency Virus (HIV) infection. The ritonavir component boosts darunavir levels by inhibiting CYP3A-mediated metabolism. This fixed-dose combination is approved as antiretroviral therapy for HIV-1 infection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects; darunavir/ritonavir 800 mg/100 mg administered orally once daily.</p><h4>References</h4><ol><li><p>Kakuda, TN, et al., &amp; Hoetelmans, RM (2014). Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food. <i>Clinical pharmacology in drug development</i> 3(5) 346–352. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.88&quot;>10.1002/cpdd.88</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27129006/&quot;>https://pubmed.ncbi.nlm.nih.gov/27129006</a></p></li><li><p>Yu, CY, et al., &amp; Morgan, RE (2014). Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. <i>Clinical drug investigation</i> 34(7) 475–482. DOI:<a href=&quot;https://doi.org/10.1007/s40261-014-0198-x&quot;>10.1007/s40261-014-0198-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24825411/&quot;>https://pubmed.ncbi.nlm.nih.gov/24825411</a></p></li><li><p>Dickinson, L, et al., &amp; Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>The Journal of antimicrobial chemotherapy</i> 75(3) 628–639. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkz479&quot;>10.1093/jac/dkz479</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31754703/&quot;>https://pubmed.ncbi.nlm.nih.gov/31754703</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end DarunavirAndRitonavir;
